Nyxoah S.A.
Nyxoah S.A. (NYXH) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nyxh · pe ratio · data through Jun 10, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Medical - Instruments & Supplies · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Nyxoah S.A.You NYXH | $52M | N/A | — | — |
 Perspective Therapeutics, Inc. CATX | $226M | N/A | — | -$1.40 |
 Genfit S.A. GNFT | $446M | 119.75x | — | $0.03 |
 Invivyd, Inc. IVVD | $135M | N/A | — | -$0.30 |
 KORU Medical Systems, Inc. KRMD | $183M | N/A | — | -$0.06 |
 OmniAb, Inc. OABI | $278M | N/A | — | -$0.57 |
 OraSure Technologies, Inc. OSUR | $286M | N/A | — | -$0.94 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Nyxoah S.A. (NYXH) measures how much investors pay for each dollar of the company's trailing earnings. NYXH's current PE ratio of N/A is calculated by dividing its stock price of $1.39 by its TTM earnings per share of —.
Frequently asked questions
NYXH pe ratio · 6 questionsNYXH's current PE ratio is N/A as of 2026-06-10, based on a stock price of $1.39 and TTM EPS of —. Data sourced from Financial Modeling Prep via NYXH's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Nyxoah S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-10